Seeking Alpha

Soligenix (SNGX.OB) is an up and coming biotech company with a large pipeline focusing on bio-therapeutic pharmaceuticals as well as bioterrorist/bio-warfare vaccines and treatments. In my last article on Soligenix we took a look at the company's current product pipeline and near-term catalysts. Since then SNGX has been picked up by Zack's Investment research and issued a "Buy" with a $4.50 price target over the next 1-3 months. As well the company has secured a new $7.1M in capital and is continuing to push full force ahead into new 2013/2014 catalysts. In this article we will take a look at the current upcoming trial milestones, partnerships and insider activity, which could be signaling investors to take...

Only subscribers can access this article, which is part of the PRO research library covering 3,773 different stocks.
Growing numbers of fund managers and other investment professionals subscribe to Seeking Alpha PRO for equity research that is unavailable elsewhere, so they can: